# Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

> **NCT05210374** · PHASE1 · RECRUITING · sponsor: **Case Comprehensive Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Relapsed Sarcomas

## Interventions

- **DRUG:** Disulfiram
- **DRUG:** Copper Gluconate
- **DRUG:** Liposomal Doxorubicin (Doxil)

## Key facts

- **NCT ID:** NCT05210374
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-09
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05210374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05210374, "Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05210374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*